Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

European Journal of Clinical Pharmacology

Volumn 51, Issue 2, 1996, Pages 117-122

  Masimirembwa, C ^a   Hasler, J ^b   Bertilssons, L ^c   Johansson, I ^a   Ekberg, O ^a   Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYPD6; Debrisoquine hydroxylase; Genotype; Phenotype; Zimbabweans;

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; METOPROLOL; METOPROLOL TARTRATE; OXYGENASE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ETHNOLOGY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; ZIMBABWE;

CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; GENOTYPE; HUMANS; METOPROLOL; MOLECULAR PROBES; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; VARIATION (GENETICS); ZIMBABWE;

EID: 0029850096     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050170     Document Type: Article

References (29)

1. Porter TD, Coon MJ (1991) Cytochrome P450: multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 266: 13469-13472
2. Ingelman-Sundberg M, Johansson I (1995) The molecular genetics of the human drug metabolizing cytochrome P450s. In: Pacifici G, Fracchia GN, (eds), Advances in drug metabolism in man. EUR 15439 EN, EC, DGXII-E-4, Luxembourg, pp 543-586
3. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 46:377-394
4. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K. Ishizaki T (1991) Metoprolol oxidation polymorphism in a Korean population. Comparison with native Japanese and Chinese population. Br J Clin Pharmacol 32:504-507
5. Eichelbaum M, Bertilsson L, Saewe J. Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31:184-186
6. McGourty JC, Silas JH, Lennard MS, Tucker GT. Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism population and family studies. Br J Clin Pharmacol 20:555-566
7. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF (1992) Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89-92
8. Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40:387-394
9. Bertilsson L, Lou YQ, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoeqvist F (1992) Pronounced difference between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388-397
10. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459
11. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K. Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype:Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558
12. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman-Sundberg M (1991) Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40:553-556
13. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg (1993) Genetic polymorphism of cytochrome P450 2D6 in a Zimbabwean population. Pharmacogenetics 3: 275-280
14. Faulker WD, King JW (1982) Renal function. In: Tietz NW (ed) Fundamentals of clinical chemistry. WB Saunders, Philadelphia. pp 986-999
15. Inaba T, Jorge LF, Arias TD (1988) Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 25:75-79
16. Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionisation and nitrogen detection. J Chromatography 133:161-166
17. Balmer K, Zhang Y, Lagerström P, Persson BA (1987) Determination of metoprolol and two major metabolites in plasma and urine by column liqiud chromatography and fluorometric detection. J Chromatography 417:357-364
18. Heim MH, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
19. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
20. Tyndale R, Aoyama T, Droly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA. Gonzalez FJ (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metaboliser phenotype, Pharmacogenetics 1:26-32
21. Oto M, Miyake S, Yuasa Y (1993) Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minilab gel electrophoresis apparatus. Anal Biochem 213: 19-22
22. Masimirembwa CM (1995) Pharmacogenetics of drug metabolising enzymes in a black African population, PhD Thesis Karolinska Institute, Stockholm
23. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 45:889-904
24. Lennard MS (1990) Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal. Pharmacol Toxicol 67:273-283
25. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP. Lin JS (1993) Genetic basis for a lower prevalence of CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91:2150-2154
26. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263
27. Armstrong M, Fairbrother K, Idle JR. Daly AK (1994). The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 4:73-81
28. Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA (1996) Lack of effect of chloroquine on the debrisoquine and S-mephenytoin hydroxylation phenotypes in black Zimbabwean and white Swedish healthy volunteers. Br J Clin Pharmacol 41:344-346
29. Lou YC (1990) Differences in drug metabolism polymorphism between Orientals and Caucasians, Drug Metab Rev 22:451-475